Enzyme engineering of cytochrome P450 RosC provides mechanistic insights into factors controlling iterative oxidation

Cytochrome P450 enzymes capable of performing iterative oxidation at the same substrate site contribute to compound diversification; however, reaction control is also necessary for the efficient production of the desired compound. RosC, a cytochrome P450 enzyme involved in the biosynthesis of the 16-membered ring macrolide antibiotic rosamicin, catalyzes stepwise oxidation of the ethyl group at C-20 via hydroxylation to an alcohol, followed by successive oxidation to the corresponding aldehyde and carboxylic acid. The P107S/L176Q mutant produces the hydroxylated intermediate in the first oxidation step, but the efficiency of the subsequent conversion to aldehyde and carboxylic acid is significantly reduced. To elucidate the factors responsible for the reduced efficiency of the second and subsequent oxidation steps in the P107S/L176Q mutant and to understand how RosC facilitates multistep oxidative modification, we compared the reaction time courses and substrate-binding affinities of RosC and the P107S/L176Q mutant. The mutant exhibited a reduced reaction rate for the initial hydroxylation and showed reduced substrate-binding affinities for both the hydroxylated and aldehydic intermediates. Furthermore, crystallographic analysis revealed that Leu-176 played a key role in binding to the desosamine moiety of the substrate, and its mutation resulted in the loss of this function. Ser-248 was presumed to play a role in re-anchoring the modification site to the active center through hydrogen bonding with the hydroxyl and aldehyde groups generated in the first and second reactions. These findings are expected to contribute to the multifunctionalization of cytochrome P450 enzymes and the regulation of their reactivity. KEY POINTS: • RosC-catalyzed three-step oxidation is limited to one step in the P107S/L176Q mutant. • P107S/L176Q mutations impair substrate binding by increasing structural fluctuations. • Leu-176 and Ser-248 position the substrate for RosC-catalyzed iterative oxidation.

Authors

Institutions

Publication Details

Journal
Applied Microbiology and Biotechnology
Published
2025-12-09
DOI
https://doi.org/10.1007/s00253-025-13648-2
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enzyme engineering of cytochrome P450 RosC provides mechanistic insights into factors controlling iterative oxidation

Yohei Iizaka, Shuji Noguchi, Hiroshi Kawasaki, Hayato Sato et al.
Applied Microbiology and Biotechnology
Pharmacogenetics and Drug Metabolism
article

Enzyme engineering of cytochrome P450 RosC provides mechanistic insights into factors controlling iterative oxidation

Yohei Iizaka, Shuji Noguchi, Hiroshi Kawasaki, Hayato Sato, Yojiro Anzai, H. Suzuki, Kazushi Fujimoto, Kihika Ishiuchi, Yuta Kumakiri, Nanako Sasa
article en

Abstract

Cytochrome P450 enzymes capable of performing iterative oxidation at the same substrate site contribute to compound diversification; however, reaction control is also necessary for the efficient production of the desired compound. RosC, a cytochrome P450 enzyme involved in the biosynthesis of the 16-membered ring macrolide antibiotic rosamicin, catalyzes stepwise oxidation of the ethyl group at C-20 via hydroxylation to an alcohol, followed by successive oxidation to the corresponding aldehyde and carboxylic acid. The P107S/L176Q mutant produces the hydroxylated intermediate in the first oxidation step, but the efficiency of the subsequent conversion to aldehyde and carboxylic acid is significantly reduced. To elucidate the factors responsible for the reduced efficiency of the second and subsequent oxidation steps in the P107S/L176Q mutant and to understand how RosC facilitates multistep oxidative modification, we compared the reaction time courses and substrate-binding affinities of RosC and the P107S/L176Q mutant. The mutant exhibited a reduced reaction rate for the initial hydroxylation and showed reduced substrate-binding affinities for both the hydroxylated and aldehydic intermediates. Furthermore, crystallographic analysis revealed that Leu-176 played a key role in binding to the desosamine moiety of the substrate, and its mutation resulted in the loss of this function. Ser-248 was presumed to play a role in re-anchoring the modification site to the active center through hydrogen bonding with the hydroxyl and aldehyde groups generated in the first and second reactions. These findings are expected to contribute to the multifunctionalization of cytochrome P450 enzymes and the regulation of their reactivity. KEY POINTS: • RosC-catalyzed three-step oxidation is limited to one step in the P107S/L176Q mutant. • P107S/L176Q mutations impair substrate binding by increasing structural fluctuations. • Leu-176 and Ser-248 position the substrate for RosC-catalyzed iterative oxidation.

Applied Microbiology and BiotechnologyVol. 109(1)
Toho University (JP)
Openalex Percentile: Top 53%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.